A Pilot Study of Exenatide Actions in Alzheimer's Disease

BACKGROUND: Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for treating type 2 diabetes, is neuroprotective and disease-modifying in Alzheimer’s Disease (AD). OBJECTIVE: We performed an 18-month double-blind randomized placebo-controlled...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Curr Alzheimer Res
Main Authors: Mullins, Roger J., Mustapic, Maja, Chia, Chee W., Carlson, Olga, Gulyani, Seema, Tran, Joyce, Li, Yazhou, Mattson, Mark P., Resnick, Susan, Egan, Josephine M., Greig, Nigel H., Kapogiannis, Dimitrios
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7476877/
https://ncbi.nlm.nih.gov/pubmed/31518224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1567205016666190913155950
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados